March 22, 2026 · The American journal of medicine · DOI: 10.1016/j.amjmed.2026.03.010

Relationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysis

Listen to this summary

This post hoc analysis of the SURMOUNT-5 trial aimed to investigate how early rapid weight loss affects the efficacy and safety of tirzepatide compared to semaglutide in obesity management. The study found that a higher proportion of participants treated with tirzepatide were rapid responders, achieving greater weight loss by Week 72, although rapid responders experienced more gastrointestinal adverse events without impacting treatment completion rates. Overall, tirzepatide demonstrated superior outcomes in weight reduction compared to semaglutide among both rapid and non-rapid responders.

Louis J Aronne, Deborah B Horn, Alexander D Kokkinos, Beverly L Falcon, Hui Wang, Hunter T Hoffmann, Clare J Lee, Julia P Dunn

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play